Fate Therapeutics, Inc.
Genomic engineering of pluripotent cells

Last updated:

Abstract:

Provided are methods and compositions for obtaining genome-engineered iPSCs, and derivative cells with stable and functional genome editing at selected sites. Also provided are cell populations or clonal cell lines derived from genome-engineered iPSCs, which comprise targeted integration of one or more exogenous polynucleotides, and/or in/dels in one or more selected endogenous genes.

Status:
Grant
Type:

Utility

Filling date:

9 Apr 2019

Issue date:

27 Jul 2021